Terms: = Lymphoma AND HIP1, ILWEQ, 3092, ENSG00000127946
18 results:
1. Primary plasmablastic lymphoma of the gastrointestinal tract: A series of 13 HIV-negative cases and a review of literature.
Fu Z; Wang H; Lauwers GY; Jiang K; Jayaratne NL; Bridglal S; Dong N; Wang E; Chen L; Barclift DP; Zhang L
Ann Diagn Pathol; 2023 Dec; 67():152204. PubMed ID: 37639839
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract] [Full Text] [Related]
3. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and hip1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological features and resistance mechanisms in hip1-ALK-rearranged lung cancer: A multicenter study.
Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
[TBL] [Abstract] [Full Text] [Related]
5. EHMT2 (G9a) activation in mantle cell lymphoma and its associated DNA methylation and gene expression.
Wang J; Xu H; Ge S; Xue C; Li H; Jing X; Liang K; Zhang X; Zhang C
Cancer Biol Med; 2021 Oct; 19(6):836-49. PubMed ID: 34633777
[TBL] [Abstract] [Full Text] [Related]
6. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
Wang CY; Sheng CC; Ma GL; Xu D; Liu XQ; Wang YY; Zhang L; Cui CL; Xu BH; Song YQ; Zhu J; Jiao Z
Acta Pharmacol Sin; 2021 Aug; 42(8):1368-1375. PubMed ID: 33154554
[TBL] [Abstract] [Full Text] [Related]
7. Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.
Tian P; Liu Y; Zeng H; Tang Y; Lizaso A; Ye J; Shao L; Li Y
J Cancer Res Clin Oncol; 2020 Apr; 146(4):935-944. PubMed ID: 31894386
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.
Couëtoux du Tertre M; Marques M; Tremblay L; Bouchard N; Diaconescu R; Blais N; Couture C; Pelsser V; Wang H; Higenell V; Izzi L; Gambaro K; Hoffert C; Srivastava A; Spatz A; Rousseau C; McNamara S; Cohen V; Batist G; Agulnik J
Mol Cancer Ther; 2019 Sep; 18(9):1628-1636. PubMed ID: 31243098
[TBL] [Abstract] [Full Text] [Related]
9. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A; de Vos S; Thieblemont C; Martin P; Flowers CR; Morschhauser F; Collins GP; Ma S; Coleman M; Peles S; Smith S; Barrientos JC; Smith A; Munneke B; Dimery I; Beaupre DM; Chen R
Blood; 2017 Apr; 129(16):2224-2232. PubMed ID: 28167659
[TBL] [Abstract] [Full Text] [Related]
10. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
[TBL] [Abstract] [Full Text] [Related]
11. Site-specific analysis of B-cell non-Hodgkin's lymphomas of the head and neck: A retrospective 10-year observation.
Takano S; Matsushita N; Oishi M; Okamoto S; Teranishi Y; Yokota C; Iguchi H
Acta Otolaryngol; 2015; 135(11):1168-71. PubMed ID: 26113048
[TBL] [Abstract] [Full Text] [Related]
12. Identification of a novel hip1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract] [Full Text] [Related]
13. Mantle cell lymphoma epidemiology: a population-based study in France.
Leux C; Maynadié M; Troussard X; Cabrera Q; Herry A; Le Guyader-Peyrou S; Le Gouill S; Monnereau A
Ann Hematol; 2014 Aug; 93(8):1327-33. PubMed ID: 24763513
[TBL] [Abstract] [Full Text] [Related]
14. A novel fusion of TPR and ALK in lung adenocarcinoma.
Choi YL; Lira ME; Hong M; Kim RN; Choi SJ; Song JY; Pandy K; Mann DL; Stahl JA; Peckham HE; Zheng Z; Han J; Mao M; Kim J
J Thorac Oncol; 2014 Apr; 9(4):563-6. PubMed ID: 24736082
[TBL] [Abstract] [Full Text] [Related]
15. hip1-ALK, a novel fusion protein identified in lung adenocarcinoma.
Hong M; Kim RN; Song JY; Choi SJ; Oh E; Lira ME; Mao M; Takeuchi K; Han J; Kim J; Choi YL
J Thorac Oncol; 2014 Mar; 9(3):419-22. PubMed ID: 24518094
[TBL] [Abstract] [Full Text] [Related]
16. hip1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract] [Full Text] [Related]
17. Aberrant Huntingtin interacting protein 1 in lymphoid malignancies.
Bradley SV; Smith MR; Hyun TS; Lucas PC; Li L; Antonuk D; Joshi I; Jin F; Ross TS
Cancer Res; 2007 Sep; 67(18):8923-31. PubMed ID: 17875735
[TBL] [Abstract] [Full Text] [Related]
18. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.
Berentsen S; Ulvestad E; Langholm R; Beiske K; Hjorth-Hansen H; Ghanima W; Sørbø JH; Tjønnfjord GE
Haematologica; 2006 Apr; 91(4):460-6. PubMed ID: 16585012
[TBL] [Abstract] [Full Text] [Related]
